B+
Bull case
25%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
COLL
Collegium PharmaceuticalANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.1
Score
AI commentary
News coverage is concentrated on the Q2 earnings print. Stored secondary earnings context describes a negative market reaction despite an adjusted-EPS beat and higher revenue guidance, while verified analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable. The evidence supports a tentative-positive monitoring view rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-09-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 earnings established ADHD momentum but exposed pain-franchise pressureMedium impact
Q2 net revenue rose 6% year over year to $199.9 million; JORNAY PM revenue rose 41% to $46.1 million and AZSTARYS contributed $12.9 million after acquisition. Management said the expanded ADHD salesforce was deployed ahead of back-to-school season, while NUCYNTA faced increased pressure. [#SEC-8K-2026-08-06]
2026-09-30catalystBack-to-school ADHD executionHigh impact
The key near-term test is prescription and prescriber momentum for JORNAY PM and AZSTARYS as the expanded commercial organization enters the back-to-school period. [#SEC-8K-2026-08-06]
2026-12-31eventASR final settlementMedium impact
The final settlement of the accelerated share repurchase agreement is expected no later than Q4 2026, providing a defined capital-allocation checkpoint. [#8-K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-02 • Updated nightlySource: Internal modelMethodology